Related references
Note: Only part of the references are listed.The Port Delivery System with ranibizumab-journey of mitigating vitreous hemorrhage
Ashish Sharma et al.
EYE (2022)
Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration
Frank G. Holz et al.
OPHTHALMOLOGY (2022)
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Nancy M. Holekamp et al.
OPHTHALMOLOGY (2022)
PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Baruch D. Kuppermann et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2021)
Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions
Thales Antonio Cabral de Guimaraes et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2021)
APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration
Michael N. Cohen et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2021)
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration A Randomized Pivotal Phase 2/3 Trial
Glenn J. Jaffe et al.
OPHTHALMOLOGY (2021)
Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
Aira Sarkar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy
Charles C. Wykoff et al.
OPHTHALMOLOGY (2021)
Age-related macular degeneration
Monika Fleckenstein et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
The Present and Future of Mitochondrial-Based Therapeutics for Eye Disease
Marco H. Ji et al.
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2021)
New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
Prem Patel et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Nanodiagnostics and Nanotherapeutics for age-related macular degeneration
Aira Sarkar et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration A Randomized Phase 2 Trial
David S. Liao et al.
OPHTHALMOLOGY (2020)
EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL
Vladimir Bantseev et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)
Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
Ivan Seah et al.
EYE (2020)
Advances in ocular drug delivery systems
Jennifer J. Kang-Mieler et al.
EYE (2020)
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2020)
Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema
Lincoln T. Shaw et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Safety and Biocompatibility of Aflibercept-Loaded Microsphere Thermo-Responsive Hydrogel Drug Delivery System in a Nonhuman Primate Model
Soohyun Kim et al.
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY (2020)
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration 52-Week Results of Phase 3 Randomized Controlled Study
Derek Kunimoto et al.
OPHTHALMOLOGY (2020)
Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19
Wioleta M. Zelek et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
Eric R. Chen et al.
CLINICAL OPHTHALMOLOGY (2020)
Issues with Intravitreal Administration of Anti-VEGF Drugs
Marc Schargus et al.
CLINICAL OPHTHALMOLOGY (2020)
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study
Kun Liu et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration Results from the Randomized Phase 2 Ladder Clinical Trial
Peter A. Campochiaro et al.
OPHTHALMOLOGY (2019)
Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and In Vitro Characterization
Priya Narvekar et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2019)
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Thierry Bordet et al.
DRUG DISCOVERY TODAY (2019)
Innovative therapies for neovascular age-related macular degeneration
Hasenin Al-Khersan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review
Norman Waugh et al.
HEALTH TECHNOLOGY ASSESSMENT (2018)
The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Monika Fleckenstein et al.
OPHTHALMOLOGY (2018)
Biosimilars in ophthalmology: Is there a big change on the horizon?
Ashish Sharma et al.
CLINICAL OPHTHALMOLOGY (2018)
Local Progression Kinetics of Geographic Atrophy in Age-Related Macular Degeneration Are Associated With Atrophy Border Morphology
Moritz Lindner et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
Rehan M. Hussain et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration A Phase 1 Dose-Escalation Study
Timothy L. Jackson et al.
JAMA OPHTHALMOLOGY (2017)
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY RETINA (2017)
Hot Topics in Dry AMD
Raja Narayanan et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Joerg T. Regula et al.
EMBO MOLECULAR MEDICINE (2016)
IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys
Xinyi Ren et al.
EXPERIMENTAL EYE RESEARCH (2016)
Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models
Anand Giddabasappa et al.
EXPERIMENTAL EYE RESEARCH (2016)
Screening for Impaired Visual Acuity in Older Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Roger Chou et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis
Yandan Zhou et al.
SCIENTIFIC REPORTS (2016)
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Andreas Plueckthun
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
High Intraocular Pressure Following Anti-Vascular Endothelial Growth Factor Therapy: Proposed Pathophysiology due to Altered Nitric Oxide Metabolism
Aaron M. Ricca et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
The Membrane Attack Complex in Aging Human Choriocapillaris Relationship to Macular Degeneration and Choroidal Thinning
Robert F. Mullins et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration Results from a 12-Month Randomized Phase 2 Study: AURORA Study
Xiaoxin Li et al.
OPHTHALMOLOGY (2014)
Intraocular Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal Age-Related Macular Degeneration Clinical Trials
Sophie J. Bakri et al.
OPHTHALMOLOGY (2014)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial
Albert J. Augustin et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Reservoir-based drug delivery systems utilizing microtechnology
Cynthia L. Stevenson et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
A Non Membrane-Targeted Human Soluble CD59 Attenuates Choroidal Neovascularization in a Model of Age Related Macular Degeneration
Siobhan M. Cashman et al.
PLOS ONE (2011)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Age-related macular degeneration - emerging pathogenetic and therapeutic concepts
Karen M. Gehrs et al.
ANNALS OF MEDICINE (2006)
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study
S Michels et al.
OPHTHALMOLOGY (2005)
Immunological factors in the pathogenesis and treatment of age-related macular degeneration
A Kijlstra et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2005)
The Rapamune era of immunosuppression 2003: The journey from the laboratory to clinical transplantation
J Camardo
TRANSPLANTATION PROCEEDINGS (2003)
Share Paper
